CBT Stock Overview
Cabot Corporation operates as a specialty chemicals and performance materials company.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Cabot Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$87.00 |
| 52 Week High | US$90.50 |
| 52 Week Low | US$58.50 |
| Beta | 1.28 |
| 1 Month Change | 5.45% |
| 3 Month Change | 28.89% |
| 1 Year Change | 37.01% |
| 3 Year Change | 87.50% |
| 5 Year Change | 114.15% |
| Change since IPO | 293.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBT | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 1.2% | -0.3% | 1.7% |
| 1Y | 37.0% | -0.3% | 2.3% |
Return vs Industry: CBT exceeded the German Chemicals industry which returned 0.2% over the past year.
Return vs Market: CBT exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| CBT volatility | |
|---|---|
| CBT Average Weekly Movement | 3.9% |
| Chemicals Industry Average Movement | 4.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CBT has not had significant price volatility in the past 3 months.
Volatility Over Time: CBT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1882 | 4,268 | Sean Keohane | www.cabotcorp.com |
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Cabot Corporation Fundamentals Summary
| CBT fundamental statistics | |
|---|---|
| Market cap | €4.84b |
| Earnings (TTM) | €404.60m |
| Revenue (TTM) | €3.67b |
12.0x
P/E Ratio1.3x
P/S RatioIs CBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBT income statement (TTM) | |
|---|---|
| Revenue | US$3.92b |
| Cost of Revenue | US$3.04b |
| Gross Profit | US$885.00m |
| Other Expenses | US$452.00m |
| Earnings | US$433.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 06, 2024
| Earnings per share (EPS) | 7.81 |
| Gross Margin | 22.55% |
| Net Profit Margin | 11.03% |
| Debt/Equity Ratio | 88.9% |
How did CBT perform over the long term?
See historical performance and comparison